PL4125802T3 - 5-amino-2,3-dihydro-1,4-ftalazinedion do leczenia ostrego uszkodzenia płuc - Google Patents

5-amino-2,3-dihydro-1,4-ftalazinedion do leczenia ostrego uszkodzenia płuc

Info

Publication number
PL4125802T3
PL4125802T3 PL21714312.2T PL21714312T PL4125802T3 PL 4125802 T3 PL4125802 T3 PL 4125802T3 PL 21714312 T PL21714312 T PL 21714312T PL 4125802 T3 PL4125802 T3 PL 4125802T3
Authority
PL
Poland
Prior art keywords
phthalazinedione
dihydro
amino
treatment
lung injury
Prior art date
Application number
PL21714312.2T
Other languages
English (en)
Inventor
Wolfgang Brysch
Astrid Kaiser
Petra Schulz
Sara SCHUMANN
Jörg VON WEGERER
Christian SETZ
Ulrich Schubert
Original Assignee
Metriopharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metriopharm Ag filed Critical Metriopharm Ag
Publication of PL4125802T3 publication Critical patent/PL4125802T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL21714312.2T 2020-03-25 2021-03-24 5-amino-2,3-dihydro-1,4-ftalazinedion do leczenia ostrego uszkodzenia płuc PL4125802T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20000133 2020-03-25
PCT/EP2021/000028 WO2021190783A1 (en) 2020-03-25 2021-03-24 5-amino-2,3-dihydro-1,4-phthalazinedione for treatment of acute lung injury

Publications (1)

Publication Number Publication Date
PL4125802T3 true PL4125802T3 (pl) 2026-03-23

Family

ID=70049815

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21714312.2T PL4125802T3 (pl) 2020-03-25 2021-03-24 5-amino-2,3-dihydro-1,4-ftalazinedion do leczenia ostrego uszkodzenia płuc

Country Status (12)

Country Link
US (1) US20230113516A1 (pl)
EP (1) EP4125802B1 (pl)
JP (1) JP7844340B2 (pl)
KR (1) KR20220158030A (pl)
CN (1) CN115768402A (pl)
AU (1) AU2021244864B2 (pl)
BR (1) BR112022019141A2 (pl)
CA (1) CA3168777A1 (pl)
ES (1) ES3057259T3 (pl)
IL (1) IL296058A (pl)
PL (1) PL4125802T3 (pl)
WO (1) WO2021190783A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3981405A1 (en) * 2020-10-08 2022-04-13 MetrioPharm AG Compound for the treatment of coronaviral infections
EP4164651B1 (en) * 2020-06-10 2025-10-15 MetrioPharm AG 5-amino-2,3-dihydro-1,4-phthalazinedione for use in the treatment of coronaviral infections
US20240075029A1 (en) * 2020-12-02 2024-03-07 Metriopharm Ag Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection
EP4193994A1 (en) * 2021-12-08 2023-06-14 MetrioPharm AG Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infections
EP4209219A1 (en) * 2022-01-07 2023-07-12 MetrioPharm AG Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione
WO2025067689A1 (en) * 2023-09-26 2025-04-03 Metriopharm Ag 5-amino-2,3-dihydro-1,4-phthalazinedione for the treatment of infections with an rna virus

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953799B1 (en) 2002-10-30 2005-10-11 Bach Pharma, Inc. Modulation of cell fates and activities by diketo phthalazines
US7326690B2 (en) * 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
EP1617805A4 (en) * 2003-04-11 2012-07-04 Medimmune Llc METHODS FOR PREVENTING OR TREATING RESPIRATORY CONDITIONS
PL231885B1 (pl) 2009-01-16 2019-04-30 Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie
WO2010096686A1 (en) * 2009-02-19 2010-08-26 Bach Pharma, Inc. Methods of treating intestinal diseases and inflammatory conditions related to hiv-aids
PT2542535E (pt) 2010-03-01 2014-08-25 Metriopharm Ag Formas cristalinas para sal de sódio de 5-amino-2,3-di hidroftalazino-1,4-diona, preparações farmacêuticas contendo o mesmo e processo para a produção das ditas formas
AU2012232670A1 (en) 2011-03-23 2013-09-12 Ariel-University Research And Development Company Ltd. Treatment of proliferative disorders with a chemiluminescent agent
WO2016096143A1 (de) 2014-12-18 2016-06-23 Metriopharm Ag Kristalline form von 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
EP3416951B1 (en) * 2016-02-16 2020-04-08 MetrioPharm AG Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione
CA3011766C (en) * 2016-02-16 2023-08-01 Metriopharm Ag Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione
EP3248602A1 (en) 2016-05-26 2017-11-29 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae
WO2018082814A1 (en) 2016-11-07 2018-05-11 Metriopharm Ag Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis
EP3511325A1 (en) 2018-01-11 2019-07-17 MetrioPharm AG Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione

Also Published As

Publication number Publication date
EP4125802B1 (en) 2025-10-01
ES3057259T3 (en) 2026-02-27
CN115768402A (zh) 2023-03-07
KR20220158030A (ko) 2022-11-29
EP4125802C0 (en) 2025-10-01
BR112022019141A2 (pt) 2023-01-17
CA3168777A1 (en) 2021-09-30
WO2021190783A1 (en) 2021-09-30
US20230113516A1 (en) 2023-04-13
EP4125802A1 (en) 2023-02-08
JP7844340B2 (ja) 2026-04-13
AU2021244864B2 (en) 2025-12-18
JP2023519526A (ja) 2023-05-11
IL296058A (en) 2022-10-01
AU2021244864A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
PL4125802T3 (pl) 5-amino-2,3-dihydro-1,4-ftalazinedion do leczenia ostrego uszkodzenia płuc
PL4164651T3 (pl) 5-amino-2,3-dihydro-1,4-ftalazinedion do stosowania w leczeniu zakażeń koronawirusowych
SG11202109452SA (en) Compounds, compositions, and methods for the treatment of disease
ZA202109003B (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
HUE071698T2 (hu) Glükokortikoid-csökkentõ szer
IL315892A (en) 5-MEO-DTM for the treatment of bipolar disorder
EP3930740A4 (en) METHODS, COMPOSITIONS, FILMS FOR THERAPEUTIC SKIN TREATMENTS
PL3737668T3 (pl) Sposób solubilizacji 5-amino-2,3-dihydro-1,4-ftalazynodionu
EP4096628C0 (en) USE OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE IN THE INHALATION TREATMENT OF INFLAMMATORY PULMONARY DISEASES
GB2605422B (en) Treatment of the central nervous system
IL299155B2 (en) Oxazolidinone compounds, liposome formulations containing oxazolidinone compounds and methods of using them
EP3982999A4 (en) COMPOSITION AND METHODS OF TREATMENT OF LIVER TISSUE DAMAGE
EP3492026A3 (en) Surgical reamer for removing bone
IL285458A (en) Combined therapy for the treatment of b-cell malignancies
GEAP202015119A (en) Antiseptic composition comprising polyvinylpyrrolidone and unithiol and use of the composition
AU2022242765A1 (en) Combined treatment of brain injury
GB202304661D0 (en) New compounds and medical uses thereof
GB2595502B (en) Compounds, compositions and methods for the treatment or prevention of hair loss
ZA202007597B (en) Method for determining treatment of orthopaedic imbalances, and apparatus therefor
GB201911728D0 (en) Bacterial composistions for the treatment of disease
GB202006236D0 (en) New treatment
GB201911056D0 (en) Treatment of ADD/ADHD
CA223597S (en) Hydrotherapy apparatus, medical apparatus
IL313638A (en) Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of congenital muscular dystrophies
AU2022901596A0 (en) Treatment or antidepressant resistant subjects